高级检索

氟桂利嗪联合倍他司汀治疗颈性眩晕的临床疗效

王富军, 张甜甜

王富军, 张甜甜. 氟桂利嗪联合倍他司汀治疗颈性眩晕的临床疗效[J]. 实用临床医药杂志, 2020, 24(11): 68-70. DOI: 10.7619/jcmp.202011019
引用本文: 王富军, 张甜甜. 氟桂利嗪联合倍他司汀治疗颈性眩晕的临床疗效[J]. 实用临床医药杂志, 2020, 24(11): 68-70. DOI: 10.7619/jcmp.202011019
shu
WANG Fujun, ZHANG Tiantian. Clinical effect of flunarizine combined with betastatin in the treatment of cervical vertigo[J]. Journal of Clinical Medicine in Practice, 2020, 24(11): 68-70. DOI: 10.7619/jcmp.202011019
Citation: WANG Fujun, ZHANG Tiantian. Clinical effect of flunarizine combined with betastatin in the treatment of cervical vertigo[J]. Journal of Clinical Medicine in Practice, 2020, 24(11): 68-70. DOI: 10.7619/jcmp.202011019
shu

氟桂利嗪联合倍他司汀治疗颈性眩晕的临床疗效

  • 陕西省安康市中医医院 药剂科, 陕西 安康, 725000

详细信息
    通讯作者:

    张甜甜,E-mail:4805223@qq.com

  • 中图分类号: R681.5

Clinical effect of flunarizine combined with betastatin in the treatment of cervical vertigo

  • Department of Pharmacy, Ankang City Hospital of Traditional Chinese Medicine, Ankang, Shaanxi, 725000

摘要

    摘要
  • 摘要: 目的 探讨氟桂利嗪联合倍他司汀治疗颈性眩晕的临床效果及对患者血管内皮素-1(ET-1)、降钙素基因相关肽(CGRP)水平的影响。 方法 选取本院收治的颈性眩晕患者120例为研究对象,按随机投掷法分为对照组和研究组。2组在基础治疗的基础上均实施中医实按灸治疗。对照组给予氟桂利嗪口服,研究组加用倍他司汀口服治疗。对比2组治疗前后眩晕障碍量表(DHI)评分、临床疗效及药物不良反应情况,同时,对比2组治疗前后ET-1、CGRP指标水平。 结果 治疗前, 2组DHI评分无显著差异(P>0.05); 研究组治疗后2、4周DHI评分显著低于对照组(P<0.05); 研究组治疗有效率为95.00%, 显著高于对照组的81.67%(P<0.05); 2组治疗前ET-1、CGRP指标水平无显著差异(P>0.05); 治疗后,研究组ET-1水平低于对照组、CGRP指标水平高于对照组,差异有统计学意义(P<0.05); 研究组不良反应发生率为16.67%, 高于对照组的11.67%, 但差异无统计学意义(P>0.05)。 结论 氟桂利嗪联合倍他司汀治疗颈性眩晕的临床效果显著,可改善颈性眩晕患者血清ET-1、CGRP指标水平。
    Abstract: Objective To investigate the clinical effect of flunarizine combined with betastatin in the treatment of cervical vertigo and its effects on vascular endothelin-1(ET-1)and calcitonin gene related peptide(CGRP)levels in patients. Methods A total of 120 patients with cervical vertigo admitted to our hospital were selected, and were divided into two groups according to random throwing method. The patients in two groups were all given pushing moxibustion therapy of traditional Chinese medicine based on basic treatment. Control group orally administrated flunarizine, while the study group was additionally given oral administration of betastatin. Dizziness Handicap Inventory(DHI)score, clinical curative effect and drug-related adverse reactions of two groups before and after treatment were compared, and ET-1, CGRP levels in the two groups before and after treatment were compared. Results There was no significant difference in DHI score between the two groups before treatment(P>0.05). DHI scores at 2 and 4 weeks after treatment in the study group were lower than those in the control group(P<0.05). The effective rate of treatment in the study group was 95.00%, which was significantly higher than 81.67% in the control group(P<0.05). There were no significant differences in the levels of ET-1 and CGRP before treatment between the two groups(P>0.05). After treatment, the level of ET-1 in the study group was lower, and the level of CGRP was significantly higher than those in the control group(P<0.05). The incidence of adverse reactions in the study group was 16.67%, which was significantly higher than 11.67% in the control group, but no significant difference was found in two groups(P>0.05). Conclusion Flunarizine combined with betastatin in the treatment of cervical vertigo has a significant clinical effect for patients with cervical vertigo, and it can improve the serum ET-1 and CGRP levels.
    • HTML全文
    • 参考文献(18)
  • 何坤, 陈彥均, 林定坤, 等. 林定坤教授三方治则治疗颈性眩晕的经验[J]. 中国中医骨伤科杂志, 2020, 28(3): 79-81.
    骆惠婷. 苯海拉明联合盐酸氟桂利嗪及山莨菪碱治疗周围性眩晕的疗效[J]. 数理医药学杂志, 2020, 33(3): 438-439.
    付衍朋, 樊兆民. Epley复位联合倍他司汀治疗后半规管良性阵发性位置性眩晕疗效的Meta分析[J]. 中华耳科学杂志, 2020, 18(1): 174-179.
    刘丰. 舒血宁联合氟桂利嗪治疗椎-基底动脉供血不足性眩晕的临床效果观察[J]. 检验医学与临床, 2020, 17(2): 158-161.
    罗恒, 刘汝专, 唐晓菊, 等. 颈性眩晕治疗研究进展[J]. 辽宁中医药大学学报, 2020, 22(2): 175-178.

    蒋智. 甲磺酸倍他司汀联合氟桂利嗪对症状性眩晕的疗效观察[J]. 北方药学, 2019, 16(12): 67-68.
    文海杰. 氟桂利嗪联合甲磺酸倍他司汀治疗老年性眩晕症患者的临床效果[J]. 河南医学研究, 2019, 28(22): 4121-4122.
    申晓稚, 卢鑫. 活血定眩方联合盐酸氟桂利嗪胶囊治疗后循环缺血性眩晕疗效观察[J]. 实用中医药杂志, 2019, 35(11): 1362-1363.
    张令媛, 韩丰丰. “托腮抬头法”、中频及氟桂利嗪综合治疗颈性眩晕30例[J]. 现代中医药, 2019, 39(6): 30-33.
    陈英, 葛叶波. 丁苯酞软胶囊联合倍他司汀治疗血管源性眩晕疗效及对氧化应激和炎性因子的影响[J]. 浙江中西医结合杂志, 2019, 29(10): 817-819.
    李皓阳. 中药补阳还五汤加味联合氟桂利嗪和倍他司汀治疗缺血性脑血管疾病的临床疗效分析[J]. 世界复合医学, 2019, 5(10): 147-149.
    穆素会. 强力定眩胶囊结合甲磺酸倍他司汀对眩晕症患者临床疗效分析[J]. 中国医学工程, 2019, 27(9): 64-66.
    林淑琴, 谢国民, 王海峰, 等. 佐米曲坦联合盐酸氟桂利嗪治疗前庭性偏头痛的疗效及对血清5-HT、CGRP的影响[J]. 现代实用医学, 2019, 31(9): 1168-1170.
    姚志城. 督脉揿针联合盐酸氟桂利嗪治疗颈性眩晕临床疗效观察[J]. 上海针灸杂志, 2018, 37(7): 797-800.
    郭红玲. 盐酸氟桂利嗪与强力定眩联合治疗颈性眩晕的疗效观察[J]. 中医临床研究, 2018, 10(16): 86-87.
    秦德芳, 刘军, 张泽舜, 等. 不同剂量颈复汤联合倍他司汀对老年颈性眩晕患者血浆ET-1及CGRP水平的影响[J]. 中国老年学杂志, 2018, 38(5): 1147-1150.
    贾应勃, 史丙利, 刘健, 等. 甲磺酸倍他司汀片联用银杏酮酯滴丸治疗颈性眩晕的临床观察[J]. 中医药导报, 2014, 20(5): 64-66.
    任耀龙, 黄景峰. 川芎嗪注射液联合西比灵胶囊配合整脊、推拿治疗颈性眩晕对照试验研究[J]. 北方药学, 2017, 14(8): 56-57.
    • 相关文章
    • 施引文献(30)

  • 期刊类型引用(11)

    1. 王轶. 注射用盐酸倍他司汀治疗眩晕症的临床效果及对炎性因子的影响. 临床合理用药. 2024(02): 48-51 . 百度学术
    2. 曾智本，吴新风. 三联疗法联合倍他司汀治疗耳石症复位后残余头晕的效果观察. 实用临床医药杂志. 2024(13): 92-97 . 本站查看
    3. 李欣龙，袁琳. 倍他司汀联合阿托伐他汀用于颈动脉斑块伴眩晕患者的疗效观察. 大医生. 2023(05): 41-43 . 百度学术
    4. 栗冰洁. 半夏白术天麻汤联合氟桂利嗪胶囊治疗周围性眩晕患者的效果. 承德医学院学报. 2023(02): 124-127 . 百度学术
    5. 刘钢招，钟丽，沈娟. 倍他司汀联合天麻钩藤饮治疗眩晕症的疗效及对脑血流动力学的影响. 现代诊断与治疗. 2023(05): 644-646 . 百度学术
    6. 金赢政，井睿智，李金江. 天麻钩藤饮联合针灸治疗后循环缺血性眩晕临床研究. 新中医. 2023(22): 53-58 . 百度学术
    7. 刘秀. 倍他司汀联合盐酸氟桂利嗪对颈性眩晕患者眩晕症状及血液流变学的影响. 现代医学与健康研究电子杂志. 2023(23): 47-49 . 百度学术
    8. 章恒端，叶旭星，胡建海. 半夏白术天麻汤联合耳穴埋豆治疗颈性眩晕的临床效果. 中国医师杂志. 2022(12): 1832-1836 . 百度学术
    9. 冷静，李红，王孝佳，董阳，韩丽丽. 后循环缺血继发眩晕给予倍他司汀及氟桂利嗪的临床干预效果评析. 中外医疗. 2022(29): 89-92 . 百度学术
    10. 许电，陈慧珍，邓恺伦. 针刺联合甲磺酸倍他司汀片对颈性眩晕患者疗效及椎基底动脉血流动力学的影响. 医学理论与实践. 2021(18): 3163-3164 . 百度学术
    11. 李晓，贺永雄，李世珅. 不同方法治疗颈性眩晕症的临床疗效比较. 内蒙古医学杂志. 2020(12): 1423-1424 . 百度学术

    其他类型引用(19)

    • 资源附件(0)
计量
  • 文章访问数: 
  • HTML全文浏览量: 
  • PDF下载量: 
  • 被引次数: 30
出版历程
  • 收稿日期:  2020-03-18
  • 网络出版日期:  2020-08-27

目录

摘要
HTML全文
    参考文献(18)
    相关文章
    施引文献
    资源附件(0)

    /

    返回文章
    返回

    © 2020 《实用临床医药杂志》编辑部

    地址：江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室邮编：225009电话：0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    本系统由 北京仁和汇智信息技术有限公司 开发  百度统计